C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 0.98 AUD -1.51% Market Closed
Market Cap: 108.9m AUD
Section:
 

Relative Value

The Relative Value of one CYC stock under the Base Case scenario is 2.52 AUD. Compared to the current market price of 0.98 AUD, Cyclopharm Ltd is Undervalued by 61%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CYC Relative Value
Base Case
2.52 AUD
Undervaluation 61%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

3.7
P/S
P/S
Price to Sales
3.7
vs History
90
vs Industry
26
Median 3Y
6
Median 5Y
6.4
Industry
2.3
Forward
3.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-19.8
Median 5Y
-28.5
Industry
22.4
Forward
-9.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-18.8
Median 5Y
-23.8
Industry
14.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-15.9
Median 5Y
-21.5
Industry
21.5
More Details
3
P/B
P/B
Price to Book Value
3
vs History
82
vs Industry
28
Median 3Y
3.7
Median 5Y
3.7
Industry
2.2
More Details
3.5
EV/S
EV/S
Enterprise Value to Sales
3.5
vs History
88
vs Industry
26
Median 3Y
5.3
Median 5Y
5.8
Industry
2.5
Forward
3.2
More Details
5.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.7
vs History
87
vs Industry
33
Median 3Y
8.2
Median 5Y
8.9
Industry
5.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-16.1
Median 5Y
-26
Industry
12
Forward
-6.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-16.1
Median 5Y
-26
Industry
17.1
Forward
-6.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-17.2
Median 5Y
-22.4
Industry
14.7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-14
Median 5Y
-20.6
Industry
18.8
More Details
2.8
EV/IC
EV/IC
Enterprise Value to IC
2.8
vs History
90
vs Industry
23
Median 3Y
5
Median 5Y
5.8
Industry
1.8
More Details

Multiples Across Competitors

CYC Competitors Multiples
Cyclopharm Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Cyclopharm Ltd
ASX:CYC
108.9m AUD 3.7 -8.1 -6.6 -6.6
US
Abbott Laboratories
NYSE:ABT
223.7B USD 5.1 16 20.4 28.4
US
Intuitive Surgical Inc
NASDAQ:ISRG
199B USD 20.6 72.3 55.5 67.7
US
Boston Scientific Corp
NYSE:BSX
136.3B USD 7 48.9 28.6 38.9
US
Stryker Corp
NYSE:SYK
134.9B USD 5.5 45.8 22.4 27.1
IE
Medtronic PLC
NYSE:MDT
126.6B USD 3.6 26.6 14.9 21.6
DE
Siemens Healthineers AG
XETRA:SHL
49.9B EUR 2.1 23.3 13.2 18.6
US
Becton Dickinson and Co
NYSE:BDX
57.1B USD 2.6 34 12.5 21.4
US
IDEXX Laboratories Inc
NASDAQ:IDXX
56B USD 13.4 54.2 39.1 43.3
US
Edwards Lifesciences Corp
NYSE:EW
48.5B USD 8.2 35.5 25.3 27.7
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
38.1B USD 1.9 17.2 12.8 15.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
C
Cyclopharm Ltd
ASX:CYC
Average EV/EBITDA: 24.5
Negative Multiple: -6.6 		N/A N/A
US
Abbott Laboratories
NYSE:ABT
20.4
12%
1.7
US
Intuitive Surgical Inc
NASDAQ:ISRG
55.5
26%
2.1
US
Boston Scientific Corp
NYSE:BSX
28.6
22%
1.3
US
Stryker Corp
NYSE:SYK
22.4
13%
1.7
IE
Medtronic PLC
NYSE:MDT
14.9
8%
1.9
DE
Siemens Healthineers AG
XETRA:SHL
13.2
11%
1.2
US
Becton Dickinson and Co
NYSE:BDX
12.5
9%
1.4
US
IDEXX Laboratories Inc
NASDAQ:IDXX
39.1
14%
2.8
US
Edwards Lifesciences Corp
NYSE:EW
25.3
13%
1.9
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
12.8
10%
1.3

See Also

Summary
CYC intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYC stock valuation using valuation multiples.
Wall Street Estimates
CYC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.